HCA(HCA) - 2025 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a 42% growth in diluted earnings per share as adjusted compared to the previous year [4] - Revenue increased by 9.6%, driven by broad-based volume growth, improved payer mix, and additional revenue from Medicaid supplemental programs [4][5] - Adjusted EBITDA margin improved due to strong performance in labor and supplies management [13] Business Line Data and Key Metrics Changes - Same facility equivalent admissions increased by 2.4% year-over-year [10] - Inpatient surgical volume grew by 1.4% and outpatient surgical volume by 1.1% [10] - Same facility total commercial equivalent admissions rose by 3.7%, with exchanges growing by 8% and commercial (excluding exchanges) by 2.4% [11] Market Data and Key Metrics Changes - Commercial and Medicare ER visits combined increased by 4.1% year-over-year, while Medicaid and self-pay ER visits declined [10] - The company experienced a slow start to the respiratory season, impacting admissions and ER visits growth rates by an estimated 50 and 70 basis points, respectively [10] Company Strategy and Development Direction - The company is focused on enhancing capacity, improving service offerings, and gaining efficiency through investments in advanced digital tools and training [5][8] - The management team has been restructured to strengthen enterprise capabilities and improve operational execution [8] - The company is advocating for the extension of enhanced premium tax credits for health insurance coverage [6] Management's Comments on Operating Environment and Future Outlook - Management expects solid demand for healthcare services to continue, with volumes projected to grow within a long-term range of 2% to 3% [7] - Operating costs are anticipated to remain stable, with some pressures in certain areas, but the resiliency plan is expected to provide relief [7] - The company is well-positioned to sustain high levels of performance in the coming years [8] Other Important Information - Cash flow from operations was $4.4 billion, with $1.3 billion in capital expenditures and $2.5 billion in share repurchases [15] - The company updated its full-year guidance, expecting revenues between $75 billion and $76.5 billion and adjusted EBITDA between $15.25 billion and $15.65 billion [16] Q&A Session Summary Question: Can you remind us what states are still pending for grandfather programs? - Management mentioned Florida, Georgia, and Virginia as states with pending applications, but they do not expect approvals during the shutdown [22] Question: Are you seeing early scheduling for surgeries due to potential coverage loss? - Management indicated that it is too early to size the potential impact of enrollment changes, but they are prepared to assist patients with coverage navigation [30] Question: Can you provide insight into the guidance range for the fourth quarter? - Management expects a solid growth rate in the high single digits for the fourth quarter, considering hurricane impacts and supplemental payment declines [36] Question: How much of the supplemental payments were recognized in the third quarter? - Tennessee was the largest driver of net benefit in the third quarter, with Texas and Kansas also contributing to the supplemental payments [39][40] Question: What is the outlook for professional fees and their impact on EBITDA? - Professional fees increased by 11% year-over-year, primarily related to anesthesia and radiology [91]